Trials / Conditions / Plasmodium Vivax Malaria

Plasmodium Vivax Malaria

14 registered clinical trials studyying Plasmodium Vivax Malaria — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Phase IIa/b Trial of PvCS/Montanide ISA-51 Malaria Vaccine in Adults in Chocó, Colombia NCT07373301	Malaria Vaccine and Drug Development Center	Phase 2
Completed	Vivax Elimination With Tafenoquine (VET) Study NCT06575647	Shoklo Malaria Research Unit	Phase 4
Recruiting	FocaL Mass Drug Administration for Vivax Malaria Elimination NCT05690841	University of California, San Francisco	Phase 3
Recruiting	Southeast Asia Dose Optimization of Tafenoquine NCT04704999	University of Oxford	Phase 4
Recruiting	ACT vs CQ With Tafenoquine for P. Vivax Mono-infection NCT05788094	Shoklo Malaria Research Unit	Phase 4
Unknown	Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand NCT05052502	University of California, San Francisco	N/A
Unknown	Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Repub NCT04416945	University of California, San Francisco	N/A
Completed	DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax NCT02123290	Medicines for Malaria Venture	Phase 2
Completed	Malaria in Early Life Study NCT02001428	Gadjah Mada University	N/A
Completed	Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam NCT01887821	Oxford University Clinical Research Unit, Vietnam	Phase 4
Terminated	Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Braz NCT01107145	Centers for Disease Control and Prevention	Phase 4
Completed	Clinical Trial for the Development of a Safe Malaria Challenge Model That Can be Reproduced in Humans NCT00935623	U.S. Army Medical Research and Development Command	Phase 1
Completed	PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria NCT00295581	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Terminated	Papua New Guinean Duffy Negativity And Vivax Malar NCT00138489	National Institute of Allergy and Infectious Diseases (NIAID)	—